Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
specificA myelodysplastic syndrome/acute myeloid leukemia that does not respond to treatment.
12
Centers
12
Active Trials
—
Cancer Funding
Top Centers for Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia(12)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 54.2 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 54.2 |
| 3 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program | 54.2 |
| 4 | Yale Cancer Center Yale School of MedicineNew Haven, CT NCI Comprehensive Active Research Program | 54.2 |
| 5 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 54.2 |
| 6 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 54.2 |
| 7 | Moffitt Cancer CenterTampa, FL NCI Comprehensive Active Research Program | 54.2 |
| 8 | VCU Massey Comprehensive Cancer CenterRichmond, VA NCI Comprehensive Active Research Program | 54.2 |
| 9 | Rutgers Cancer InstituteNew Brunswick, NJ NCI Comprehensive Active Research Program | 54.2 |
| 10 | University of Illinois Cancer CenterChicago, IL Active Research Program | 54.2 |
| 11 | Boston University Cancer CenterBoston, MA Active Research Program | 54.2 |
| 12 | Cancer Center at IllinoisUrbana, IL Active Research Program | 54.2 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →